Prostate Cancer Therapeutics Market Analysis By Drugs (Zytiga, Gonax, Lupron, Zoladex, Decapeptyl, Eligard, Vantas, Casodex, Xtandi, Taxotere, Jevtana, Provenge, Xofigo), By Region, And Segment Forecasts, 2014 - 2025

  • ID: 4312504
  • Report
  • 90 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • Astella, Inc.
  • Astrazeneca
  • Bayer AG
  • IPSEN
  • Johnson & Johnson
  • Sanofi Aventis
  • MORE
The global prostate cancer therapeutics market is expected to reach USD 12.0 billion by 2025. According to the American Cancer Society, approximately 1 in 7 men will be diagnosed with prostate cancer in their lifetime. As per Cancer Research, a government institute, in the UK, 46,690 new cases of prostate cancer were diagnosed out of which 11,287 patients died in 2014.

Supportive initiatives undertaken by key players in collaboration with various governments to create more awareness of clinical symptoms about prostate cancer and availability of screening & diagnostic tests such as Prostate-Specific Antigen (PSA) and Digital Rectal Exam (DRE) resulting in early detection. Early detection helps in quick and on time treatment and assists in deciding treatment regimens. In addition, major players including Astella, Inc., Sanofi, Dendreon Corporation, AstraZeneca, and Johnson & Johnson are focusing on development of effective and safe therapeutic products to treat tumor. Moreover, these players have various established brands such as Zytiga, Xtandi, Eligard, Taxotere, Provenge, and Xofigo, which hold a strong position in the market. In addition, there are many drugs in pipeline such as Tc-99m (Progenics), radium-223 dichloride (Xofigo, Bayer), and ODM-201 (Orion and Bayer), which are in their phase 3 studies and are expected to enter the market during the forecast period. In addition, patents of many existing products are expiring during the forecast period. As a result, generic products are anticipated to penetrate the market. All these factors together are expected to propel growth.

In Canada, Prostate Cancer Foundation of Canada supports research, cure, and prevention of prostate cancer through an online portal. This portal provides detailed information regarding symptoms, diagnosis, and commercially available treatment options. Such portals offer free access to people all around the world, which is resulting in growth.

Further key findings from the study suggest:
  • The growing incidence of prostate cancer across the globe is expected to drive growth
  • The market is segmented into hormonal therapy including Luteinizing Hormone Releasing Hormone (LHRH) agonist, LHRH antagonist & antiandrogen; chemotherapy; immunotherapy, and targeted therapy
  • Zytiga (Johnson & Johnson) is considered as a gold standard product for the treatment of prostate cancer and holds a strong position. However, Xtandi (Astella, Inc.) and Zytiga are competing with each other. The degree of competition is projected to elevate during the forecast period. Thus, hormonal therapy holds the largest share.
  • Provenge (Dendreon Corporation) is the only immunotherapy drug mainly used in the treatment of advanced or metastasis of such cancerous cells
  • In addition, there are many promising immunotherapy drugs in the pipeline such as INO-5150 SynCon and PROSTVAC (Bavarian Nordic), which are expected to enter the market in the near future. Thus, this drug class is projected to be the fastest growing segment.
  • North America dominated the global market. Rising prevalence and mortality rate associated with such tumors in the U.S. is the primary reason for the dominance of the region.
  • Asia Pacific is anticipated to be the fastest growing region over the forecast period. Rising awareness regarding prostate cancer in Asian countries including China, Japan, & India, would be the major factor driving the growth.
  • Some of the major players include, but are not limited to, Johnson & Johnson; Astella, Inc.; Sanofi; Ipsen; Bayer AG; AstraZeneca; Valeant Pharmaceuticals North America LLC (Dendreon Corporation). These major players dominate the market owing to their strong brand identity and extensive geographic reach.
PLEASE NOTE: This report will be completed after order and will take approximately 1-2 business days after the confirmation of payment.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Astella, Inc.
  • Astrazeneca
  • Bayer AG
  • IPSEN
  • Johnson & Johnson
  • Sanofi Aventis
  • MORE
1 Research Methodology
1.1 Information Procurement
1.2 Data Analysis
1.3 List of Data Sources
2 Executive Summary
2.1 Market Snapshot
3 Prostate Cancer Therapeutics Market Variables, Trends & Scope
3.1 Market segmentation& scope
3.1.1 Market Driver Analysis
3.1.1.1 Rising rate of prostate cancer cases
3.1.1.2 Technological advancement in screening and diagnostic tests
3.1.1.3 Rising awareness of prostate cancer
3.1.2 Market Restraint Analysis
3.1.2.1 High cost associated with diagnostic tests and treatment of prostate cancer
3.2 Penetration & Growth Prospect Mapping
3.3 Prostate Cancer Therapeutics Market - PESTLE Analysis
3.4 Industry Analysis - Porter’s
4 Prostate Cancer Therapeutics: Drugs Class Estimates & Trend Analysis
4.1 Prostate Cancer Therapeutics Market: Drug Class Movement Analysis
4.2 Hormonal Therapy
4.2.1 Hormonal Therapy Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
4.2.2 Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
4.2.2.1 Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists Market Estimates, 2014 - 2025 (USD Billion)
4.2.3 Zytiga
4.2.3.1 Zytiga Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
4.2.4 Gonax
4.2.4.1 Gonax Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
4.2.5 Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
4.2.5.1 Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Market Estimate & Segment Forecast, 2014 - 2025 (USD Billion)
4.2.6 Lupron
4.2.6.1 Lupron Market Estimate & Segment Forecast, 2014 - 2025 (USD Billion)
4.2.7 Zoladex
4.2.7.1 Zoladex Market Estimate & Segment Forecast, 2014 - 2025 (USD Billion)
4.2.8 Eligard
4.2.8.1 Eligard Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
4.2.9 Decapeptyl
4.2.9.1 Decapeptyl Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
4.2.10 Vantas
4.2.10.1 Vantas Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
4.2.11 Others
4.2.11.1 Others Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
4.2.12 Anti-Androgen
4.2.12.1Anti-androgen Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
4.2.13 Xtandi
4.2.13.1 Xtandi Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
4.2.14 Casodex
4.2.14.1 Casodex Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
4.3 Chemotherapy
4.3.1 Chemotherapy Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
4.3.2 Taxotere
4.3.2.1 Taxotere Market Estimates, 2014 - 2025 (USD Billion)
4.3.3 Jevtana
4.3.4.1 Jevtana Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
4.4 Immunotherapy
4.4.1 Immunotherapy Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
4.4.2 Provenge
4.4.2.1 Provenge Market Estimates, 2014 - 2025 (USD Billion)
4.5 Targeted Therapy
4.5.1 Targeted Therapy Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
4.5.2 Xofigo
4.5.2.1 Xofigo Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
5 Prostate Cancer Therapeutics: Regional Estimates & Trend Analysis, by Drug Class
5.1 Prostate Cancer Therapeutics Market Share By Region, 2016 & 2025
5.2 North America
5.2.1 North America prostate cancer therapeutics market estimates & segment forecast, 2014 - 2025 (USD Billion)
5.2.2 U.S.
5.2.2.1 U.S. prostate cancer therapeutics market estimates & segment forecast, 2014 - 2025 (USD Billion)
5.2.3 Canada
5.2.3.1C anada prostate cancer therapeutics market estimates & segment forecast, 2014 - 2025 (USD Billion)
5.3 Europe
5.3.1 Europe prostate cancer therapeutics market estimates & segment forecast, 2014 - 2025 (USD Billion)
5.3.2UK
5.3.2.1 UK prostate cancer therapeutics market estimates & segment forecast, 2014 - 2025 (USD Billion)
5.3.3 Germany
5.3.3.1 Germany prostate cancer therapeutics market estimates & segment forecast, 2014 - 2025 (USD Billion)
5.4 Asia Pacific
5.4.1 Asia Pacific prostate cancer therapeutics market estimates & segment forecast, 2014 - 2025 (USD Billion)
5.4.2 China
5.4.2.1 China prostate cancer therapeutics market estimates & segment forecast, 2014 - 2025 (USD Billion)
5.4.3 Japan
5.4.3.1 Japan prostate cancer therapeutics market estimates & segment forecast, 2014 - 2025 (USD Billion)
5.5 Latin America
5.5.1 Latin America prostate cancer therapeutics market estimates & segment forecast, 2014 - 2025 (USD Billion)
5.5.2 Brazil
5.5.2.1 Brazil prostate cancer therapeutics market estimates & segment forecast, 2014 - 2025 (USD Billion)
5.5.4 Mexico
5.5.4.1 Mexico prostate cancer therapeutics market estimates & segment forecast, 2014 - 2025 (USD Billion)
5.6 MEA
5.6.1 MEA prostate cancer therapeutics market estimates & segment forecast, 2014 - 2025 (USD Billion)
5.6.2 South Africa
5.6.2.1 South Africa prostate cancer therapeutics market estimates & segment forecast, 2014 - 2025 (USD Billion)
6 Competitive Landscape
6.1 Company Profiles
6.1.1 Johnson & Johnson
6.1.1.1 Company overview
6.1.1.2 Financial Performance
6.1.1.3 Product benchmarking
6.1.1.4 Strategic initiatives
6.1.2. Astella, Inc.
6.1.2.1 Company overview
6.1.2.2 Financial Performance
6.1.2.3 Product benchmarking
6.1.2.4 Strategic Initiatives
6.1.3 Sanofi Aventis
6.1.3.1 Company overview
6.1.3.2 Financial Performance
6.1.3.3 Product benchmarking
6.1.3.4 Strategic initiatives
6.1.4 IPSEN
6.1.4.1 Company overview
6.1.4.2 Financial Performance
6.1.4.3 Product benchmarking
6.1.4.4 Strategic initiatives
6.1.5 Bayer AG
6.1.5.1 Company overview
6.1.5.2 Financial Performance
6.1.5.3 Product benchmarking
6.1.5.4 Strategic initiatives
6.1.6 Astrazeneca
6.1.6.1 Company overview
6.1.6.2 Financial Performance
6.1.6.3 Product benchmarking
6.1.6.4 Strategic initiatives
6.1.7. Valent Pharmaceuticals LLC
6.1.7.1 Company overview
6.1.7.2 Financial Performance
6.1.7.3 Product benchmarking
6.1.7.4 Strategic initiatives

List of Tables

Table 1 North America prostate cancer therapeutics market, by drug class 2014 - 2025 (USD Billion)
Table 2 North America hormonal therapy market, 2014 - 2025 (USD Billion)
Table 3 North America (LHRH) antagonists market, 2014 - 2025 (USD Billion)
Table 4 North America (LHRH) agonist market, 2014 - 2025 (USD Billion)
Table 5 North America (LHRH) ant-androgen market, 2014 - 2025 (USD Billion)
Table 6 North America chemotherapy market, 2014 - 2025 (USD Billion)
Table 7 North America immunotherapy market, 2014 - 2025 (USD Billion)
Table 8 North America targeted therapy market, 2014 - 2025 (USD Billion)
Table 9 US prostate cancer therapeutics market, by drug class 2014 - 2025 (USD Billion)
Table 10 US hormonal therapy market, 2014 - 2025 (USD Billion)
Table 11 US (LHRH) antagonists market, 2014 - 2025 (USD Billion)
Table 12 US (LHRH) agonist market, 2014 - 2025 (USD Billion)
Table 13 US (LHRH) ant-androgen market, 2014 - 2025 (USD Billion)
Table 14 US chemotherapy market, 2014 - 2025 (USD Billion)
Table 15 US immunotherapy market, 2014 - 2025 (USD Billion)
Table 16 US targeted therapy market, 2014 - 2025 (USD Billion)
Table 17 Canada prostate cancer therapeutics market, by drug class 2014 - 2025 (USD Billion)
Table 18 Canada hormonal therapy market, 2014 - 2025 (USD Billion)
Table 19 Canada (LHRH) antagonists market, 2014 - 2025 (USD Billion)
Table 20 Canada (LHRH) agonist market, 2014 - 2025 (USD Billion)
Table 21 Canada (LHRH) ant-androgen market, 2014 - 2025 (USD Billion)
Table 22 Canada chemotherapy market, 2014 - 2025 (USD Billion)
Table 23 Canada immunotherapy market, 2014 - 2025 (USD Billion)
Table 24 Canada targeted therapy market, 2014 - 2025 (USD Billion)
Table 25 Europe prostate cancer therapeutics market, by drug class 2014 - 2025 (USD Billion)
Table 26 Europe hormonal therapy market, 2014 - 2025 (USD Billion)
Table 27 Europe (LHRH) antagonists market, 2014 - 2025 (USD Billion)
Table 28 Europe (LHRH) agonist market, 2014 - 2025 (USD Billion)
Table 29 Europe (LHRH) ant-androgen market, 2014 - 2025 (USD Billion)
Table 30 Europe chemotherapy market, 2014 - 2025 (USD Billion)
Table 31 Europe immunotherapy market, 2014 - 2025 (USD Billion)
Table 32 Europe targeted therapy market, 2014 - 2025 (USD Billion)
Table 33 UK prostate cancer therapeutics market, by drug class 2014 - 2025 (USD Billion)
Table 34 UK hormonal therapy market, 2014 - 2025 (USD Billion)
Table 35 UK (LHRH) antagonists market, 2014 - 2025 (USD Billion)
Table 36 UK (LHRH) agonist market, 2014 - 2025 (USD Billion)
Table 37 UK (LHRH) ant-androgen market, 2014 - 2025 (USD Billion)
Table 38 UK chemotherapy market, 2014 - 2025 (USD Billion)
Table 39 UK immunotherapy market, 2014 - 2025 (USD Billion)
Table 40 UK targeted therapy market, 2014 - 2025 (USD Billion)
Table 41 Germany prostate cancer therapeutics market, by drug class 2014 - 2025 (USD Billion)
Table 42 Germany hormonal therapy market, 2014 - 2025 (USD Billion)
Table 43 Germany (LHRH) antagonists market, 2014 - 2025 (USD Billion)
Table 44 Germany (LHRH) agonist market, 2014 - 2025 (USD Billion)
Table 45 Germany (LHRH) ant-androgen market, 2014 - 2025 (USD Billion)
Table 46 Germany chemotherapy market, 2014 - 2025 (USD Billion)
Table 47 Germany immunotherapy market, 2014 - 2025 (USD Billion)
Table 48 Germany targeted therapy market, 2014 - 2025 (USD Billion)
Table 49 Asia Pacific prostate cancer therapeutics market, by drug class, 2014 - 2025 (USD Billion)
Table 50 Asia Pacific hormonal therapy market, 2014 - 2025 (USD Billion)
Table 51 Asia Pacific (LHRH) antagonists market, 2014 - 2025 (USD Billion)
Table 52 Asia Pacific (LHRH) agonist market, 2014 - 2025 (USD Billion)
Table 53 Asia Pacific (LHRH) ant-androgen market, 2014 - 2025 (USD Billion)
Table 54 Asia Pacific chemotherapy market, 2014 - 2025 (USD Billion)
Table 55 Asia Pacific immunotherapy market, 2014 - 2025 (USD Billion)
Table 56 Asia Pacific targeted therapy market, 2014 - 2025 (USD Billion)
Table 57 China prostate cancer therapeutics market, by drug class, 2014 - 2025 (USD Billion)
Table 58 China hormonal therapy market, 2014 - 2025 (USD Billion)
Table 59 China (LHRH) antagonists market, 2014 - 2025 (USD Billion)
Table 60 China (LHRH) agonist market, 2014 - 2025 (USD Billion)
Table 61 China (LHRH) ant-androgen market, 2014 - 2025 (USD Billion)
Table 62 China chemotherapy market, 2014 - 2025 (USD Billion)
Table 63 China immunotherapy market, 2014 - 2025 (USD Billion)
Table 64 China targeted therapy market, 2014 - 2025 (USD Billion)
Table 65 Japan prostate cancer therapeutics market, by drug class 2014 - 2025 (USD Billion)
Table 66 Japan hormonal therapy market, 2014 - 2025 (USD Billion)
Table 67 Japan (LHRH) antagonists market, 2014 - 2025 (USD Billion)
Table 68 Japan (LHRH) agonist market, 2014 - 2025 (USD Billion)
Table 69 Japan (LHRH) ant-androgen market, 2014 - 2025 (USD Billion)
Table 70 Japan chemotherapy market, 2014 - 2025 (USD Billion)
Table 71 Japan immunotherapy market, 2014 - 2025 (USD Billion)
Table 72 Japan targeted therapy market, 2014 - 2025 (USD Billion)
Table 73 Latin America prostate cancer therapeutics market, by drug class, 2014 - 2025 (USD Billion)
Table 74 Latin America hormonal therapy market, 2014 - 2025 (USD Billion)
Table 75 Latin America (LHRH) antagonists market, 2014 - 2025 (USD Billion)
Table 76 Latin America (LHRH) agonist market, 2014 - 2025 (USD Billion)
Table 77 Latin America (LHRH) ant-androgen market, 2014 - 2025 (USD Billion)
Table 78 Latin America chemotherapy market, 2014 - 2025 (USD Billion)
Table 79 Latin America immunotherapy market, 2014 - 2025 (USD Billion)
Table 80 Latin America targeted therapy market, 2014 - 2025 (USD Billion)
Table 81 Brazil prostate cancer therapeutics market, by drug class, 2014 - 2025 (USD Billion)
Table 82 Brazil hormonal therapy market, 2014 - 2025 (USD Billion)
Table 83 Brazil (LHRH) antagonists market, 2014 - 2025 (USD Billion)
Table 84 Brazil (LHRH) agonist market, 2014 - 2025 (USD Billion)
Table 85 Brazil (LHRH) ant-androgen market, 2014 - 2025 (USD Billion)
Table 86 Brazil chemotherapy market, 2014 - 2025 (USD Billion)
Table 87 Brazil immunotherapy market, 2014 - 2025 (USD Billion)
Table 88 Brazil targeted therapy market, 2014 - 2025 (USD Billion)
Table 89 Mexico prostate cancer therapeutics market, by drug class, 2014 - 2025 (USD Billion)
Table 90 Mexico hormonal therapy market, 2014 - 2025 (USD Billion)
Table 91 Mexico (LHRH) antagonists market, 2014 - 2025 (USD Billion)
Table 92 Mexico (LHRH) agonist market, 2014 - 2025 (USD Billion)
Table 93 Mexico (LHRH) ant-androgen market, 2014 - 2025 (USD Billion)
Table 94 Mexico chemotherapy market, 2014 - 2025 (USD Billion)
Table 95 Mexico immunotherapy market, 2014 - 2025 (USD Billion)
Table 96 Mexico targeted therapy market, 2014 - 2025 (USD Billion)
Table 97 MEA prostate cancer therapeutics market, by drug class, 2014 - 2025 (USD Billion)
Table 98 MEA hormonal therapy market, 2014 - 2025 (USD Billion)
Table 99 MEA (LHRH) antagonists market, 2014 - 2025 (USD Billion)
Table 100 MEA (LHRH) agonist market, 2014 - 2025 (USD Billion)
Table 101 MEA (LHRH) ant-androgen market, 2014 - 2025 (USD Billion)
Table 102 MEAchemotherapy market, 2014 - 2025 (USD Billion)
Table 103 MEA immunotherapy market, 2014 - 2025 (USD Billion)
Table 104 MEA targeted therapy market, 2014 - 2025 (USD Billion)
Table 105 South Africa prostate cancer therapeutics market, by drug class 2014 - 2025 (USD Billion)
Table 106 South Africa hormonal therapy market, 2014 - 2025 (USD Billion)
Table 107 South Africa (LHRH) antagonists market, 2014 - 2025 (USD Billion)
Table 108 South Africa (LHRH) agonist market, 2014 - 2025 (USD Billion)
Table 109 South Africa (LHRH) ant-androgen market, 2014 - 2025 (USD Billion)
Table 110 South Africa chemotherapy market, 2014 - 2025 (USD Billion)
Table 111 South Africa immunotherapy market, 2014 - 2025 (USD Billion)
Table 112 South Africa targeted therapy market, 2014 - 2025 (USD Billion)

List of Figures

Figure 1 Market research process
Figure 2 Information procurement
Figure 3 Primary research pattern
Figure 4 Market research approaches
Figure 5 Value chain based sizing & forecasting
Figure 6 QFD modelling for market share assessment
Figure 7 Market summary
Figure 8 Market trends & outlook
Figure 9 Market segmentation & scope
Figure 10 Market driver relevance analysis (Current & future impact)
Figure 11 Market restraint relevance analysis (Current & future impact)
Figure 12 Penetration & Growth Prospect Mapping
Figure 13 Prostate Cancer Therapeutics Market PESTLE Analysis
Figure 14 Porter’s Five Forces Analysis
Figure 15 Prostate Cancer Therapeutics Market Drug Class Outlook Key Takeaways
Figure 16 Prostate Cancer Therapeutics Market: Drug Class Movement Analysis
Figure 17 Hormonal Therapy Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
Figure 18 Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
Figure 19 Zytiga Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
Figure 20 Gonax Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
Figure 21 Luteinizing Hormone-Releasing Hormone (LHRH) AgonistsMarket Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
Figure 22 Lupron Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
Figure 23 Zoladex Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
Figure 24 Eligard Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
Figure 25 DecapeptylMarket Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
Figure 26 Vantas Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
Figure 27 Others Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
Figure 28 Anti-androgen Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
Figure 29 Xtandi Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
Figure 30 Casodex Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
Figure 31 Chemotherapy Therapy Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
Figure 32 Taxotere Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
Figure 33 Jevtana Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
Figure 34 Immunotherapy Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
Figure 35 Provenge Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
Figure 36 Targeted Therapy Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
Figure 37 Xofigo Market Estimates & Segment Forecast, 2014 - 2025 (USD Billion)
Figure 38 Regional Market Place: Key Takeaways
Figure 39 Regional outlook, 2016 & 2025
Figure 40 North America prostate cancer therapeutics market, 2014 - 2025 (USD Billion)
Figure 41 U.S. prostate cancer therapeutics market, 2014 - 2025 (USD Billion)
Figure 42 Canada prostate cancer therapeutics market, 2014 - 2025 (USD Billion)
Figure 43 Europe prostate cancer therapeutics market, 2014 - 2025 (USD Billion)
Figure 44 UK prostate cancer therapeutics market, 2014 - 2025 (USD Billion)
Figure 45 Germany prostate cancer therapeutics market, 2014 - 2025 (USD Billion)
Figure 46 Asia Pacific prostate cancer therapeutics market, 2014 - 2025 (USD Billion)
Figure 47 China prostate cancer therapeutics market, 2014 - 2025 (USD Billion)
Figure 48 Japan prostate cancer therapeutics market, 2014 - 2025 (USD Billion)
Figure 49 Latin America prostate cancer therapeutics market, 2014 - 2025 (USD Billion)
Figure 50 Brazil prostate cancer therapeutics market, 2014 - 2025(USD Billion)
Figure 51 Mexico prostate cancer therapeutics market, 2014 - 2025 (USD Billion)
Figure 52 MEA prostate cancer therapeutics market, 2014 - 2025 (USD Billion)
Figure 53 South Africa prostate cancer therapeutics market, 2014 - 2025 (USD Billion)
Figure 54 Strategy framework
Figure 55 Participant categorization
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Johnson & Johnson
  • Astella, Inc.
  • Sanofi Aventis
  • IPSEN
  • Bayer AG
  • Astrazeneca
  • Valent Pharmaceuticals LLC
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll